VERSION 1 -AUTHOR RESPONSE
Reviewers' Comments to Author:
Reviewer: 1 Reviewer Name: Marco Russo, MD, PhD Institution and Country: Azienda USL IRCCS Reggio Emilia, Italy Please state any competing interests or state 'None declared': None declared
In this well-conducted large case-control study the authors highlight the importance of GP in early diagnosis of brain tumors. The results confirm that some symptoms alone (in particular headache) have low usefulness in brain tumors diagnosis. This is important in order to avoid unecessary brain CT or MRI in patients with a long history of headache.
I would like to ask to the authors how they explain the fact that seizure, weakness and confusion had higher predictive values than many other symptoms in primary care. In fact, usually these symptoms lead firstly the patients to the Emergency Department.
We thank the reviewer for their positive comments. We agree that particularly for a new onset generalised seizure, patients are most likely to present directly to the Emergency Dept and may or may not have seen their GP for a prior related complaint. Weakness and confusion, especially in older patients are likely to be seen both in primary care and emergency departments. Patients with focal seizures may well present first to their GP.
For new onset seizure and weakness we believe the higher PPV relates to the greater specificity of these symptoms for a structural abnormality, although even here there are several alternative and more common diagnoses. The higher PPV of new onset confusion when compared to many other symptoms is interesting and an important finding that we are exploring further in patients in the clinic.
Furthermore, is it possible to obtain from electronic records information about the clinical characteristics of headache in patients diagnosed with brain tumour? Did they have an history of primary headache (migraine, tension-type)?
In theory yes as there are codes for these features but in practice GPs often simply used the generic headache code, so analysis of the more granular terms are of limited value.
Reviewer: 2 Reviewer Name: Elka Humphrys Institution and Country: University of Cambridge, UK Please state any competing interests or state 'None declared': None declared This paper addresses an important topic, as there is limited research relating to symptomatic presentation of adult brain tumours and how earlier diagnosis can be achieved. I would very much like to see this study published; however, there are some major revisions required to the current manuscript, which I have outlined in the attached review, along with further minor revisions. I have referenced the page number, line number and occasionally included quotes from the manuscript to illustrate my comments and assist with completion of the corrections.
Introduction
Page 4, line 44: References 3 and 4 do not seem appropriate here. Reference 3 is a letter describing various studies. Relevant references should therefore be extracted from the letter, with the original studies referenced in the current manuscript. Reference 4 is a paediatric brain tumour study, therefore should only be included if it is explicit in the text that the study was in children and therefore may not map to adult brain tumours.
We thank the reviewer for highlighting these references which have been incorrectly cited. These have been amended Page 5, lines 25-35: The structure of this section suggests that a mathematical model has indicated that a delay to radiotherapy could have a negative effect on survival9, yet observational studies do not support this10. However, reference 10 only included one brain tumour study, therefore the observational evidence is itself limited. Reference 9 only included glioblastoma, the most aggressive form of brain tumour, therefore these results may not be applicable to other brain tumour types. The wording of this section should clarify the limitations of the referenced studies.
We have amended the wording as suggested Material and methods Page 7, line 37: The justification for choosing to examine headache and cognitive symptoms is based on the results of reference 8. However, this study states that headache and memory loss were important, not headache and cognitive problems. 'Cognitive' in reference 8 was split in to confusion and memory loss. Therefore what was the justification for using 'cognitive problems' in the current study rather than just memory loss? Also, where is memory loss categorised in the symptom groupings in appendix II?
Our previous paper (Reference 8) actually classified symptom groups into (i) headache; (ii) behavioural/cognitive change; (iii) focal neurology including stroke; (iv) episodic attacks-'fits, faints and falls'; (v) non-specific neurological; and (vi) other/non-specific features. The reviewer is correct in that we further sub-divided behavioural/cognitive change into confusion and memory only subgroups. This was a small study based on only 226 cases and not using READ code groups so there were far fewer possible groupings. As we explained in the methods, we created symptom dictionaries so memory problems are classified under the broader heading of cognitive (now renamed as cognition -see response below for further details). We present the data for cognition and confusion separately in table 2 but when we used the combinations of headache plus cognitive it was pragmatically more sensible to combine these smaller sub-groups.
Statistical analyses
General comments: Which software (and version number) was used for the analysis? What p-value was deemed significant?
We used Stata 15 for the analysis (added to the text) and the conventional p-value of 0.05 however, we try to avoid the rigid dichotomization of statistical significance at this arbitrary cut-point as recommended by the American Statistical Society so have not highlighted this in the text.
Statistical tests: I am unsure as to the statistical methods used. The analysis section refers to regression or Chi-squared tests, diagnostic utilities (sensitivity, specificity, PPVs, PLRs), conditional logistic regression, diagnostic odds ratios (DORs) and multinominal logistic regression. The abstract refers to sensitivity, specificity, PPVs, PLRs, DORs and conditional logistic regression. However, 'conditional logistic regression' along with 'regression or Chi-squared tests' and 'multinominal logistic regression' are not mentioned in the results section of the manuscript. Were these latter methods used and if so, where/how? Yes all these methods were used. As this was a matched case control study, it is standard procedure to use conditional logistic regression with a dichotomous outcome (case or control). Multinomial logistic was only used for the primary and secondary tumour versus control analysis as this are unordered binary outcomes. We have clarified this in the results section.
Page 9, line 27: Why were age groups stratified to <60, 60-69, ≥70? The justification was a previous publication (reference 5), however, this reference used 10 year age bands.
On page 3 (column 2) of the Hamilton and Kernick (2007) paper they state that the peak likelihood ratio and PPVs were in the age band 60-69 years, hence we wanted to test this statement by creating three groups <60, 60-69 >=70 years Results Page 11, line 46: Within the manuscript there is a symptom group labelled 'cognitive' and a combination of symptom groups (cognitive + concentration + confusion) also referred to as cognitive. As cognitive symptoms are a major focus of the paper, it would be easier to understand the narrative if a different phrase was used to define cognitive + concentration + confusion vs 'cognitive' without the additional symptoms. For example, page 11, line 46 refers to 'cognitive symptoms' in relation to primary tumours. Does this mean the symptom group 'cognitive' or the cognitive combination?
Thank you for highlighting this potential confusion -we also struggled with the nomenclature. We have used the umbrella term "cognitive" for the symptom group and "cognition" for the individual symptom and have altered the text in the paper and tables and appendix.
Page 11, line 37: The results state that for seizure and visual symptoms, patients aged <70 years had much higher DORs than older patients. While this appears true for seizure based on results in table 4 (<60 = 89.3, 60-69 = 70, ≥70 = 14.5) the same cannot be said for visual symptoms (<60 =22.8, 60-69 = 5.11, ≥70 = 4.9) as the 60-69 age band is very similar to the ≥70 age band (5.11 vs 4.9).
Thank you for highlighting this. The statement is factually correct in that patients under 70 years (if you combine the < 60 and 60-69 age bands) do have higher DORs than those ≥70 age band. However the reviewer is correct to state that this is predominantly driven by the < 60 year group so we have clarified this.
Discussion
Page 15, line 6: The conclusion referring to the "majority of referred patients not having a brain tumour" is not a conclusion based on the results of the study as 'referrals' for symptoms has not been covered in the results of this manuscript.
We have amended this sentence Page 15, line 11: The final concluding point relates to diagnostic tests for GPs, which was only briefly mentioned in the discussion. Is the major conclusion from this study that symptomatic assessment is not the most appropriate way to diagnose patients with brain tumours?
Not at all but rather it is very difficult to get the diagnosis right in the absence of other biomarkers or tests. We are trying to reassure GPs that this is a very difficult diagnosis for all practitioners. Table 1 There is a major error in table 1 in the cases column. The total number of cases should be 8,184 yet the totals for gender, age and Charlson index each add up to 8,423. Where have these extra 239 cases come from and has this error affected any of the other tables/results? Thank you for spotting this error -the table was put together before we spotted that in our original data extraction of cases, some cases of meningioma had been erroneously included though we had tried to exclude them in our original code list. These were then dropped. The table should have been updated which has now occurred and the numbers are now consistent. Table 3 What is the difference between 'Headache + cognitive' and 'Cognitive + headache'? Headache + cognitive has 47 cases and a PPV of 5.9. Cognitive + headache has 111 cases and a PPV of 7.2. The difference between the categories is not explained anywhere, yet the latter result is one of the major study findings.
We did explain this difference in the footnote with the ** but we agree that the nomenclature was confusing (a point the reviewer has made earlier). So to clarify headache + cognition is the combination of headache plus only cognitive problems e.g. memory complaint, whilst Cognitive+ headache is the composite of cognitive, concentration and confusion symptoms plus headache so they are not the same as hence the numbers are different.
Minor issues Abstract Page 2, line 6: Consider using 'presented' rather than 'presenting' to primary care as symptoms do not present to GPs, they are presented.
Introduction
Page 4, line 6: The incidence of brain tumours is stated as "5 per 100,000 person years". Can this be stated in an easier format to understand i.e. brain tumours as a percentage of all cancers? (Currently 3% in UK, 2015; Cancer Research UK). Either way, the statistic needs a reference.
The incidence statistic comes from reference 1 which is actually cited in the next sentence. We have decided to amend this statistic as we have now found a better systematic review paper which cites a higher value of 25 per 100,000 and we have added this to the citations. We respectfully disagree with the reviewer as her comment is answering a different question. Of all cancers how common are brain tumours whilst we are asking in the general population what is your risk of developing a brain tumour. Both are valid questions, but the population risk is more relevant for what we are looking at as this will determine the predictive value of symptoms. We have rephrased our wording which we hope will make this easier to follow.
Page 4, lines 46 & 54: Reference 5 is included in the first sentence of this paragraph (previous studies) and then again as a study found within the systematic review. I would suggest only referencing it when discussing the systematic review.
We respectfully disagree and think it is more helpful to reference it twice for greater clarity.
Page 4, line 46: The full stop should be in front of reference 5. We have made this amendment Page 4, line 49: The full stop should be in front of reference 6. We have made this amendment Page 4, line 49 to page 5, line 14: Two studies from the systematic review are discussed; one case control and one case cohort. The paragraph structure would be improved by introducing the case control study and describing it, and then moving on to the case cohort with description. The current structure introduces the case control study, then the case cohort, then the narrative goes back to the case control, and then it goes back to the case cohort.
We agree with the reviewer and have amended the order.
Page 5, line 23: Is there a time-span associated with "…attended their GP more frequently before referral" i.e. attended their GP more frequently 'in the six months' before referral? The reference to '8' would also be better placed at the end of this sentence, rather than the following one.
According to the NACDPC methodology there was no specific time frame but rather "Participating practices were asked to count all consultations relating to the presenting problem that was associated with the patient's cancer."
We feel the reference citation is appropriate and have not altered this.
Material and methods
Page 5, line 30: Is 'prognosis' the correct term to use in this sentence: "We excluded meningiomas because of their very different prognosis." As the study was exploring symptom presentation, were meningiomas not excluded based on how patients present with them in primary care rather than the prognosis?
Yes -we excluded meningiomas because of their better prognosis but we agree they may also present differently and many are identified incidentally. We have amended this.
Page 6, line 6: 'U.K.' should be changed to 'UK' to match the format throughout the manuscript.
We have made this amendment Page 6, line 27: Consider using the full word for January and December, rather than abbreviating them to Jan and Dec.
We have made this amendment Page 6, lines 25-47: The inclusion/exclusion criteria have been briefly described here; however, were any controls excluded? In relation to other exclusion criteria, the sentence "patients had to come from a practice with at least six months of up-to-standard data before diagnosis" suggests that practices were excluded where records were not up to date -is this correct? In the results, it states that 1.2% of cases and 18.6% of controls were excluded based on individual patients not having a GP visit within six months of diagnosis. I would recommend including this as an exclusion criteria in this section.
The case inclusion criteria clearly do not apply to controls whilst the practice exclusion apply to both cases and controls. We have added the exclusion for potential ghost patients to the methods section as suggested.
Page 7, line 20: Can an example be given where individual symptoms were aggregated into larger groups due to small numbers? As this is also mentioned again in the strengths and limitations (p13, lines 32-35) section, it would be useful to have more details of this in the methods section to fully understand the discussion.
We have added further explanation with an exemplar around visual symptoms Page 7, lines 23-25: The following sentence, "this generated 32 independent symptom groups and 23 more neurologically-related symptoms", reads as though there are 32 independent groups + 23 neurological = 55 symptom groups total. It should read '32 independent symptom groups, of which 23 were neurologically-related symptoms'.
We have made this amendment Page 7, line 27: Vomiting is referenced as a symptom group in this sentence, "to examine consistency, we compared our Read codes for some symptom groups (e.g. weight loss, vomiting, etc)", yet is not included in the Appendix II. Has this been included in another symptom category?
Yes -we added this to the group labelled nausea. We have added a footnote to appendix II.
Page 7, line 30: The 'cancer diagnostic study (led by WHa)' needs a reference.
We have added a reference Page 7, lines 30-32: Was it necessary to append any additional missing codes as referred to in this sentence: "…to check for completeness and, if necessary, appended any additional codes that we had missed"? Very occasionally. We have amended this Page 7, line 51: It is unclear in this section why the one month and six month time scales were chosen. There is a section on page 10, lines 13-25 that would provide clarity in the methods: "We chose this time-period rather than 1 year……….the natural history of brain tumours.15" However, can a difference reference be used as this one only relates to glioblastomas.
We actually provided justification for the varying time windows in the statistical analysis section page 8 lines 61-66 where we stated "We initially looked at a variety of different latency periods prior to the index date: 1 month, 3 months, 6 months, and 1 year, as we were not certain of the optimum retrospective time-period to evaluate. "The results of this analysis then influenced how we looked at the combinations as that followed temporally in our analysis. We have clarified this in the paper. We are unable to find another better reference though we accept that our cases also include secondary tumours so have a made a comment on this.
Results
Page 9, line 58: 's' is required on the end of 'month' in this sentence: "…GP visit 6 month prior…".
We have amended this Page 10, line 30: This line states that "23 of the32 symptom groups differed between cases and controls" -is this why only 23 symptom groups were included in table 2? It would be useful to make this more explicit in the text and as a footnote to table 2.
Yes -we have made this more explicit both in the text and in the title of table 2. Page 11, lines 8-11: See comments on table 3 (major issues) querying the difference between headache + cognitive and cognitive + headache.
We have answered this above Discussion Page 12, line 8: References 6 and 8 do not seem appropriate for supporting the findings that 'seizures, confusion and weakness' are most predictive. Reference 6 is the systematic review, which in turn refers to references 5 and 7. Reference 5 is appropriate but reference 7 focuses on headache. In addition, reference 8 relates to headache and memory loss.
We agree that reference 6 simply refers back to reference 5 so have dropped this. However reference 8 does indeed provide weaker evidence in relation to confusion and weakness though in the paper the term focal neurology is used. We have amended the sentence accordingly. We have clarified this Page 13, line 49: Reference 20 relates to free-text coding by the GP, which is not the same as saying that the GP did not code symptoms, as suggested in the sentence preceding this reference.
The reviewer is correct and we have amended this sentence to better reflect the paper as well as highlight the speculative nature of our suggestion. We have amended this Page 15, line 11: Consider re-phrasing "…over the last 6 months…" to 'in the 6 months prior to diagnosis' as this adds clarity to the sentence.
We have amended this Table 1 General formatting: (%) would be better placed at the top of columns two and three as it is relevant for all results i.e n=… (%). The symbol can then be removed from beside Male and Female. Within the columns, percentages have been formatted with a mixture of 0, 1 or 2 decimal points. The table would benefit from a consistent format throughout i.e. one decimal place for all percentages.
We have amended this Table 2 Ataxia/gait: Why has gait been added to Ataxia? In appendix II it is just listed as Ataxia. Pain: Appendix II lists General Pain. Consistency across the tables/appendices would be good.
We have amended this and appendix to be consistent Table 3 Time scales: The table title and the * footer refer to a 6 month period, yet the results in the table also relate to the one month assessment. Can the wording relating to one month and six months be clarified?
We have altered the table to make the relevant time windows clearer Table 4 Column labels: It would be helpful to label the three main columns to indicate that the results are the diagnostic odds ratio i.e. 'Diagnostic odds ratio for age groups'. Currently this is only apparent based on the title of the table.
We have amended this Appendix I Column labels: It would be helpful to include column titles to identify the CPRD medcodes vs the Read codes. Data: In the second column, I am unsure why there are blank spaces. Can this be clarified? Meningioma: I am unsure why meningiomas were included in the list of relevant Read codes mapped to CPRD medcodes if meningiomas were excluded from the analysis. Can this be clarified?
This was an error as explained earlier and have now been removed. We have rectified the missing pathological labels
